Table 2.

Treatment schedules and follow-up of eight patients with NEN treated with ICI.

No.	Surgery	Locoregional procedures/Radiotherapy/PRRT	Chemotherapy/targeted therapy/SSA	ICI therapy agent	Outcome and duration of therapy	ICI-related-side effects	Follow-up 02/2020
1	04/2010 local resection of left ary cartilage08/2012 right neck dissection with lymph node resection02/15 right orchiectomy09/16 resection of cutaneous metastasis	11/16 stereotactic radiation of orbital metastasis (54 Gy)06/17 stereotactic radiation of cerebral metastases (49,4 Gy)11/17 stereotactic radiation of cerebellar metastasis (25,6 Gy)10/18 stereotactic radiation of retrotracheal lymph node	11/12-02/14 temozolomide12/14-09/15 FOLFOX06-09/16 everolimus10/16-03/17 CAP/TEM	04/17-01/20 pembrolizumab	PR, 31 months	No	Alive, PD after 32 months PR
2	01/05 right nephrectomy07/07 lymphadenectomy04/10 retrocaval tumor with partial resection of the inferior vena cavalymphadenectomy	04/13-01/16 PRRT (3cycles)11/14- 01/18 TAE (5 cycles)05/18-06/18 SIRT01/19 brachytherapyin afterloading technique	09/10-03/13 SSA05/12-12/12 everolimus + SSA06/16-09/17 TEM/CAP	Since 10/19 pembrolizumab	PR, at least 3 months	No	Alive, PR
3	None	10/16 Brachytherapy in afterloading technique	08/12-06/13 FOLFOX 06/13-01/17 CAP/TEM 01-04/17 Everolimus04-05/17 FOLFIRI	Since 07/17 pembrolizumab	PR at least 30 months	Recurrent pneumonitis	Alive, PR
4	11/10 atypical partial gastric resection, resection of multiple liver metastasis12/11 anterior rectal resection with appendectomy, splenectomy, parietal peritonectomy with omentectomy and HIPEC11/13 relaparotomy with tumor debulking05/14 resection of pancreatic lymph node09/14 resection of metastases of the skin03/16 resection of peritoneal metastases, HIPEC02/17 robot-assisted mediastinal lymphadenectomy	01/11-11/11 TACE (3 cycles)03-09/11 PRRT01/13-12/16Brachytherapyin afterloading technique (5 cycles)04/16 radiosurgery of metastasis of sacral bone (20Gy)	10/10 sandostatin01-04/12 CAP/TEM (12cycles)02-04/12 ipilimumab04-07/13 peginterferon alpha2b08/13-12/14 immunotherapy including vaccination of transfected autologous tumor03/16 HIPEC08/16 – 04/17 immunotherapy including vaccination of transfected autologous tumor03/17 sunitinib06/17 everolimus	09-11/14 pembrolizumab11/14-06/16 pembrolizumab + ipilizumab08/16 atezolizumab04/17-10/19 pembrolizumab + ipilizumab	SD at least 35 months	Recurrent pneumonitis	Alive, SD
5	04/15 partial pancreaticoduodenectomy with partial resection of the stomach08/17 liver wedge resection	None	02-04/16 STU/5FU06-09/09 CAP/TEM09-12/16 FOLFOX-IV01-07/17 everolimus12/17-03/18 sunitinib	03-05/18 pembrolizumab	PD, 3 months	No	Death (06/18)
6	None	04-10/16 PRRT (3 cycles)	01/14-12/14 CAP/TEM 11/15 STZ/5-FU 02-05/17 FOLFOX 05/17 FOLFIRI 12/17-02/18 everolimus 03-05/18 sunitinib 06-10/18 CAP/TEM	09-11/18 avelumab	PD, 3 months	No	Death (12/18)
7	04/12 right and left s hemicolectomy09/15 resection of diaphragm metastasis12/17 diagnostic laparoscopy	11/2018 radiotherapy of pleural metastases	04-08/12 cisplatin/etoposide09/16-01/17 FOLFOX01-10/17 FOLFIRI11/18-06/19 CAP/TEM	03-09/18 pembrolizumab	PD, after 6 months SD	Diarrhea, asthma, sleep disorder	Alive, PD
8	None	None	03/17- 01/18 carboplatin /etoposide02-05/2018 FOLFOX605-07/2018 FOLFIRI	09/18-11/18 pembrolizumab	PD, 3 months	No	Death (02/19)